Every woman deserves prevention that is natural and accessible.
Oncelia is developing PHIBRA, the first connected bra combining bioimpedance and thermography for the early detection of breast cancer.
- Non-invasive
- Radiation-free
- Accessible to all women
Everyday peace of mind
Gentle monitoring, at home
Breast cancer, by the numbers
Global epidemiology
1 in 8
women will develop breast cancer in their lifetime
INCa (French National Cancer Institute) · Cancer Overview 2024
2.3M → 3.2M
new cases in 2022 → 2050 projection
IARC / Nature Medicine · Feb. 2025
Screening & genetic risk
~50%
of eligible women in France actually take part in organized screening
Santé publique France · 2024
1 in 5
breast cancers occurs in a woman under 50, who is not covered by organized screening
INCa (French National Cancer Institute) · Cancer Overview 2024
90-95%
of cancers occur in women with no identified hereditary mutation (BRCA1/2)
BCRF · WHO 2026
The missing link in prevention
Breast cancer is the most common cancer among women in 157 out of 185 countries. Current methods — mammography, ultrasound — are effective but only offer a snapshot in time, and are out of reach or simply not offered to many women. An essential link is missing to tighten the prevention safety net: regular, earlier, comfortable monitoring at home.
“The solution exists. It's called PHIBRA.”
Prevention, finally personalized
The app gets to know you and automatically recommends the monitoring frequency best suited to your situation.
- 1
Your profile, your protocol
Age, hormonal status, medical history, genetic mutation, latest exams: the app analyzes your risk profile and immediately assigns you a personalized monitoring frequency.
- 2
Phase 01 · Calibration
The app learns your unique tissue signature and establishes your reference profile — the baseline that makes any deviation detectable.
- 3
Phase 02 · Longitudinal monitoring
Gentle reminders, month-by-month tracking of your curve, and an alert in case of significant deviation.
Product image
To be configured in /admin/reglages
Clinical study
Image to be configured in /admin/reglages
84.6%
Sensitivity
76.9%
Specificity
40
Patients
PHIBRA, more than just a concept
Pilot study conducted at the Hospices Civils de Lyon under principal investigator Prof. Marion Cortet — PHIBRA protocol vs. mammography on a prototype, 15-minute measurement, 40 patients.
Study detailsFrequently asked questions
Everything you want to know about PHIBRA — clear answers, no jargon.
No, PHIBRA is still in development. This website is for information only: it lets you follow Oncelia's news and PHIBRA's progress.
PHIBRA is intended for all women who want earlier, more regular and more reassuring breast monitoring — to keep a closer eye on their breast health and ease anxiety between check-ups. It is particularly suited to:
- Women at high genetic risk (BRCA1/2 mutation) and/or with a family history
- Women under 50, for whom mammography screening is generally not yet recommended
- Women undergoing treatment or in remission, as part of enhanced monitoring
- Women living far from healthcare facilities or with reduced mobility
- Women over 74, who are no longer included in organized screening programs
- Women who have had ovarian cancer or Hodgkin lymphoma
Both. Initially, PHIBRA will mainly be used at home — available directly or through supplemental health insurers and employers, as part of prevention programs.
At a later stage, it will also be offered in partner medical practices: midwives, community gynecologists, urban health centers and occupational health services.
Absolutely not. PHIBRA complements existing medical exams. It enables earlier, more frequent monitoring between appointments and may flag anomalies that warrant further investigation. Getting your mammograms at the recommended frequency remains essential.
Yes. The first PHIBRA clinical study (first-in-human) was conducted at the Hospices Civils de Lyon (HCL) under the direction of Prof. Cortet, with 40 patients. The results were published in Sensors (MDPI) in May 2026: 83.3% sensitivity, 71.5% specificity.
The protocol adapts to your profile: a calibration phase followed by longitudinal monitoring. You'll find all the details in the PHIBRA Usage section.
Absolutely not. PHIBRA uses two 100% harmless, non-invasive technologies: bioimpedance (a very low-intensity current you cannot feel — just like in smart scales) and thermography (reading the body's natural heat). No radiation, no compression.
Yes. Your data is pseudonymized from the moment it is collected, hosted on certified HDS servers (the French standard for health data hosting) and processed in compliance with the GDPR. A multi-level consent framework lets you control precisely how it is used. Your privacy is a design priority, not an option.
Join the Oncelia movement.
There's a place for everyone in our journey.
I'm an investor
Download our investor memo and get in touch with the founding team.
I'm a healthcare professional
Access the clinical summary and express your interest in a partnership or a pilot study.
I'm a partner / member of the press
Press kit, partnership deck, interview requests — we reply within 48 hours.